In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion

http://

Latest From Celltrion

EU New Drug Approvals Hit Record High

Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.

Europe Approvals

Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

Biosimilars Coronavirus COVID-19

Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope

The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.

Ophthalmic M & A

Novartis’s Ligelizumab Founders In Phase III Despite Positive Predictions

Novartis’s ligelizumab failed to show superiority over standard of care Xolair, subverting hopeful analyst expectations and changing the firm’s focus in chronic spontaneous urticaria to a BTK inhibitor asset.

Clinical Trials Inflammation
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register